The ubiquitin-conjugating enzyme E2-EPF is overexpressed in cervical             cancer and associates with tumor growth.
We found that the ubiquitin-conjugating enzyme E2-EPF mRNA is highly expressed             in cervical squamous cancer relative to normal tissues and its expression levels             positively correlate with clinical stage. Reduction of E2-EPF protein levels by             >80% using shRNA decreases the expression levels of HIF-1α, and the proliferation,             invasion and tumorigenicity of SiHa, a cervical squamous cancer cell line. E2-EPF             knockdown also increases the chemosensitivity to topoisomerase I inhibitor (topotecan)             and II (etoposide and doxorubicin). Our results suggest that E2-EPF is associated             with the growth and aggressivity of cervical tumor cells. Targeting the E2-EPF             pathway may have potential clinical applications for the treatment of cervical             cancer.
Department of Obstetrics and Gynecology, China-Japan Friendship Hospital, Beijing, PR China.
Jing
J
Liang
Hirotaka
H
Nishi
Mei-Lu
ML
Bian
Chinatsu
C
Higuma
Toru
T
Sasaki
Hiroe
H
Ito
Keiichi
K
Isaka
D000818:Animals; D002294:Carcinoma, Squamous Cell / Q000235:genetics / Q000473:pathology; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D004317:Doxorubicin / Q000494:pharmacology; D005047:Etoposide / Q000494:pharmacology; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D055785:Gene Knockdown Techniques; D006801:Humans; D051795:Hypoxia-Inducible Factor 1, alpha Subunit / Q000235:genetics; D051379:Mice; D008819:Mice, Nude; D017239:Paclitaxel / Q000494:pharmacology; D011401:Promoter Regions, Genetic; D034741:RNA, Small Interfering; D012016:Reference Values; D059004:Topoisomerase I Inhibitors / Q000494:pharmacology; D059003:Topoisomerase Inhibitors / Q000494:pharmacology; D019772:Topotecan / Q000494:pharmacology; D044763:Ubiquitin-Conjugating Enzymes / Q000235:genetics* / Q000378:metabolism; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology*
C497442:HIF1A protein, human; D051795:Hypoxia-Inducible Factor 1, alpha Subunit; D034741:RNA, Small Interfering; D059004:Topoisomerase I Inhibitors; D059003:Topoisomerase Inhibitors; D005047:Etoposide; D019772:Topotecan; D004317:Doxorubicin; C544962:Ube2S protein, human; D044763:Ubiquitin-Conjugating Enzymes; D017239:Paclitaxel